Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc.

Bullboard Posts

Comment by Maceron Feb 14, 2020 10:45am

187 Views

Post# 30691348

RE:RE:RE:Evaluation of a Ruthenium coordination complex FEB 2020

vestor111 wrote: Better yet - a link to the PDF.

https://onlinelibrary.wiley.com/doi/epdf/10.1002/tbio.201900032

Very interesting read.
Nice to see some pre-clinical phamacokinetic data being collected in two species with IV administration. TLD 1433 blows photofrin out of the water on everything they studied by comparison. The potential ability to target MIBC sounds really interesting and feasible as well.
Love that they are already looking beyond treating just NMIBC. Tells me that they are confident that phase 2 will demonstrate exactly what they expect and that they are moving on to a more encompassing treatment for all bladder CA patients.
Macer

Bullboard Posts

Debt-free cannabis company set for next stage of growth